A sudden departure
18/09/23 -"Out of the blue has come the departure of Mr Pierre-Alain Ruffieux only four weeks before the investors day. In our view, this might have happened after some strategic discussions about future ..."
Pages
69
Language
English
Published on
18/09/23
You may also be interested by these reports :
17/09/26
Although our estimates have increased by double digits, the target price has been raised at a lower rate due to Ipsen’s near- and mid-term risks. ...
15/09/26
At a time when Novartis and AstraZeneca nurse a run of late-stage R&D setbacks, GSK’s recent clinical trial successes for oncology candidates, ...
14/09/26
Since its July 2022 listing, Haleon (BUY; UK) has delivered a total return of just under 20%. Unexciting, but not for want of progress. Assembled ...
11/09/26
The recent R&D setbacks in cardiovascular and neuroscience areas have prompted us to revise our target price downwards. In the process, we have also ...